News | September 02, 2009

Abbott Launches Next-Generation XIENCE PRIME DES in International Markets

The XIENCE PRIME DES

September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.

XIENCE PRIME, which received CE mark in June, offers a new stent design and a delivery system designed for greater flexibility and enhanced deliverability. XIENCE PRIME is now widely available in Europe and in select countries throughout Asia-Pacific and Latin America.

"Abbott's XIENCE PRIME is an improvement in design, deliverability and conformability, all of which can be distinctly observed during coronary stent procedures, in both everyday and complex lesions," said Antonio Bartorelli, M.D., director of the interventional cardiology department of the Centro Cardiologico Monzino, University of Milan, Italy. "XIENCE PRIME is designed to be easily deliverable even in complex cases and very long lesions."

XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott's market-leading XIENCE V Everolimus-Eluting Coronary Stent System. XIENCE PRIME is based upon the design used in the MULTI-LINK VISION family of stents, which is the most widely used stent platform in the world – more than 2 million of Abbott's cobalt chromium stents have been implanted worldwide.

"XIENCE PRIME leverages the superior outcomes from the extensive body of clinical evidence from the SPIRIT family of clinical trials, and offers design and delivery system properties that make it even easier for a physician to appropriately reach and treat a lesion," said Patrick Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcenter, Erasmus University Hospital, Rotterdam, the Netherlands. "The XIENCE PRIME stent is designed to improve stent deliverability, minimize vessel injury and provide easy access to lesions in complex anatomy."

XIENCE PRIME uses cobalt chromium technology, and has one of the thinnest DES struts available, while maintaining strength to support the vessel. It provides excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is available in a broad size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions.

For more information: www.xiencev.com

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init